<?xml version="1.0" encoding="UTF-8"?>
<p>As a positive control for in vitro and in vivo experiments, the non-halogenated anthracycline doxorubicin was analyzed. Doxorubicin is used as a chemotherapeutic agent for the treatment of breast cancer patients. Doxorubicin exhibited higher toxicity against MDA-MB-231 cells in vitro (IC
 <sub>50</sub> = 0.71 ± 0.05 µM) [
 <xref rid="B27-molecules-26-00366" ref-type="bibr">27</xref>] and antiproliferative and apoptosis-inducing activity in vivo (
 <xref ref-type="fig" rid="molecules-26-00366-f008">Figure 8</xref>) than the boswellic acids analyzed in the present study. However, doxorubicin induces severe adverse effects, like cardio- and nephrotoxicity [
 <xref rid="B56-molecules-26-00366" ref-type="bibr">56</xref>,
 <xref rid="B57-molecules-26-00366" ref-type="bibr">57</xref>], whereas, for 
 <italic>Boswellia</italic> extracts and boswellic acids, no adverse effects were observed in mouse studies [
 <xref rid="B11-molecules-26-00366" ref-type="bibr">11</xref>,
 <xref rid="B12-molecules-26-00366" ref-type="bibr">12</xref>,
 <xref rid="B58-molecules-26-00366" ref-type="bibr">58</xref>] and only mild adverse effects such as heartburn or nausea have been reported in clinical studies [
 <xref rid="B3-molecules-26-00366" ref-type="bibr">3</xref>].
</p>
